The Hong Kong-listed innovative drug sector has recently shown clear signs of strength, with both the CXO and innovative drug segments rising in tandem, rapidly boosting market sentiment. $WUXI APPTEC (02359.HK)$ Represented by industry leaders alone, H-shares have hit record highs, driving increased attention to the sector. More importantly, fundamentals for Hong Kong’s innovative drug companies are undergoing systematic improvement: on one hand, order volumes in the CXO industry continue to recover; on the other, innovative drug firms are entering a dual-engine phase driven by commercialization realization and business development (BD). Overall, the sector is transitioning from 'expectation repair' to 'earnings validation,' prompting the market to reprice the value of R&D pipelines and commercialization capabilities. Do you favor the cyclical recovery of CXOs or the long-term growth potential of innovative drug companies?